NCT00094107 - Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

MelanomaSkin Neoplasms

Interventions

DRUG

Axitinib [AG-013736]

VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.

Trial Locations (12)

15025

Pfizer Investigational Site, Clairton

15090

Pfizer Investigational Site, Wexford

15232

Pfizer Investigational Site, Pittsburgh

15601

Pfizer Investigational Site, Greensburg

15901

Pfizer Investigational Site, Johnstown

33140

Pfizer Investigational Site, Miami Beach

75651

Pfizer Investigational Site, Paris

92868

Pfizer Investigational Site, Orange

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

02215

Pfizer Investigational Site, Boston

15232-1305

Pfizer Investigational Site, Pittsburgh